Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Matthew S. Davids, Jeff P. Sharman, Toby A. Eyre, Jennifer A. Woyach, Paulo Andre P. de Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd

Blood (2022) 140 (Supplement 1): 4173–4175.

https://doi.org/10.1182/blood-2022-157018

Published: 2022

Journal Articles

Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Matthew S. Davids, Ugochinyere Emeribe, Priyanka Gaitonde, Ling Cai

Blood (2021) 138 (Supplement 1): 2633.

https://doi.org/10.1182/blood-2021-146976

Published: 2021

Journal Articles

A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients

John F. Seymour, Priyanka Gaitonde, Ugochinyere Emeribe, Ling Cai, Anthony R. Mato

Blood (2021) 138 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2021-147112

Published: 2021

Journal Articles

Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Matthew S. Davids, Anthony R. Mato, Juliette Hum, Susana Wargo, Ugochinyere Emeribe, Mina Shahkarami, Kevin Sokolowski, Juliana M.L. Biondo, Sarang Abhyankar, Rick Hermann, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2021-148155

Published: 2021